ArticleClinical medicine (London, England)2020
Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment.
Article in Clinical medicine (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.Hepatology international · 2025Guideline
- Discrete Choice Experiments and Conjoint Analyses in Health Screening Programs for Type 2 Diabetes and Liver Disease: A Scoping Review.Canadian liver journal · 2025Pooled it
- Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review.Journal of molecular medicine (Berlin, Germany) · 2024Pooled it
- Demand, Waitlisting and Transplantation Around the World: The Axiomatic View of Scarcity in Liver Transplantation.Clinical transplantation · 2026Article
- Body Mass Index Outperforms Triglyceride-Glucose Index in Predicting MAFLD in Type 2 Diabetes: A Cross-Sectional Mediation and Interaction Analysis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- [Analysis of a study for the global trend burden of MAFLD-associated cirrhosis based on the 2024 update of the Global Burden of Disease Database].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Non-invasive blood biomarkers for assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2025Review
- Peri-Complication Diagnosis of Nonalcoholic Fatty Liver Disease: A US Population-Based Retrospective Analysis.Digestive diseases (Basel, Switzerland) · 2025Article
- Qualitative service evaluation of a multimodal pilot service for early detection of liver disease in high-risk groups: 'Alright My Liver?'BMJ open gastroenterology · 2024Article
- Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis.World journal of gastrointestinal pharmacology and therapeutics · 2024Review
- The Scottish Hepatology Access Research Partnership (SHARP) improving access to liver services throughout Scotland.NIHR open research · 2024Article
- Global epidemiology of cirrhosis - aetiology, trends and predictions.Nature reviews. Gastroenterology & hepatology · 2023Review
- Exploring changing attitudes to non-invasive liver fibrosis tests in secondary care pathways: comparison of two national surveys.Frontline gastroenterology · 2023Article
- Two-Tier Care Pathways for Liver Fibrosis Associated to Non-Alcoholic Fatty Liver Disease in HIV Mono-Infected Patients.Journal of personalized medicine · 2022Article
- Identification of liver disease: why and how.Frontline gastroenterology · 2022Review
- Article
- Uncovering unsuspected advanced liver fibrosis in patients referred to alcohol nurse specialists using the ELF test.BMC gastroenterology · 2021Article
- Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment.Frontiers in medicine · 2021Review
- COVID-19: the physician's response in the first phase.Clinical medicine (London, England) · 2020Article
- The NAFLD Decompensation Risk Score: External Validation and Comparison to Existing Models to Predict Hepatic Events in a Retrospective Cohort Study.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) accounts for 10-15% of orthotopic liver transplants (OLTs) in the UK. Index presentations with cirrhotic decompensation represent missed opportunities for preventive treatment leaving OLT or palliation as the only options.We retrospectively reviewed patient records for all NAFLD patients undergoing assessment for OLT between January 2003 and December 2017.Data were available for 81 patients with NAFLD as the primary diagnosis. Fifty-two patients had decompensated cirrhosis at first presentation; 91.7% presented to secondary care compared to 52.7% referred from primary care (p=0.001). Cirrhosis was not suspected at the time of referral to hospital in 24.7% of patients subsequently assessed for OLT. Most patients undergoing assessment for OLT for NAFLD had decompensated cirrhosis at their first diagnosis of chronic liver disease. These data highlight the plight of patients with NAFLD cirrhosis in whom chronic liver disease is diagnosed late.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.